There may be the very rare patient on an aliskerin-based product for hypertension that are not on an ACEI or ARB, but that population is going to be very, very small.
The new 7000 patient showed the drug did not kill people, nor did it help very much in preventing symptoms either, when compared to patients that were treated aggressively with standard therapy.